Protagonist Therapeutics, INC (PTGX) — 8-K Filings

8-K Filings (18)

• Protagonist Therapeutics Files 8-K on Financials — Aug 6, 2025 Risk: low
  Protagonist Therapeutics, Inc. filed an 8-K on August 6, 2025, reporting on its results of operations and financial condition, as well as financial statements a
• Protagonist Therapeutics Files 8-K on Shareholder Vote Matters — Jun 26, 2025 Risk: low
  Protagonist Therapeutics, Inc. filed an 8-K on June 26, 2025, reporting on matters submitted to a vote of security holders as of June 20, 2025. The filing does
• Protagonist Therapeutics Files 8-K on Financials — May 6, 2025 Risk: low
  Protagonist Therapeutics, Inc. filed an 8-K on May 6, 2025, reporting on its results of operations and financial condition, as well as financial statements and
• Protagonist Therapeutics Files 8-K — Mar 20, 2025 Risk: low
  On March 17, 2025, Protagonist Therapeutics, Inc. filed an 8-K report. The filing indicates that the company is a pharmaceutical preparations company incorporat
• Protagonist Therapeutics Files 8-K — Mar 10, 2025 Risk: low
  Protagonist Therapeutics, Inc. filed an 8-K on March 10, 2025, reporting other events and financial statements as of March 8, 2025. The filing does not contain
• Protagonist Therapeutics Files 8-K — Mar 3, 2025 Risk: low
  On March 3, 2025, Protagonist Therapeutics, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits." No s
• Protagonist Therapeutics Files 8-K on Financials — Feb 21, 2025 Risk: low
  Protagonist Therapeutics, Inc. filed an 8-K on February 21, 2025, reporting on its results of operations and financial condition, and providing financial statem
• Protagonist Therapeutics Announces Executive and Director Compensation Changes — Jan 6, 2025 Risk: low
  Protagonist Therapeutics, Inc. announced on January 1, 2025, changes in its executive and director compensation arrangements. The filing details the election of
• Protagonist Therapeutics Files 8-K: Material Agreement — Nov 18, 2024 Risk: medium
  On November 13, 2024, Protagonist Therapeutics, Inc. entered into a Material Definitive Agreement. The filing also notes other events and includes financial sta
• Protagonist Therapeutics Files 8-K — Nov 7, 2024 Risk: low
  Protagonist Therapeutics, Inc. filed an 8-K on November 7, 2024, reporting on its results of operations and financial condition, as well as financial statements
• Protagonist Therapeutics Appoints New CMO, Adds Director — Sep 20, 2024 Risk: medium
  Protagonist Therapeutics, Inc. announced on September 17, 2024, the appointment of Dr. Jonathan G. Drachman as Chief Medical Officer and the election of Ms. Sar
• Protagonist Therapeutics Files 8-K — Aug 6, 2024 Risk: low
  On August 6, 2024, Protagonist Therapeutics, Inc. filed an 8-K report. The filing primarily concerns the company's financial condition and results of operations
• Protagonist Therapeutics Elects Directors, Ratifies Auditors — Jun 26, 2024 Risk: low
  On June 20, 2024, Protagonist Therapeutics, Inc. filed an 8-K report detailing the results of its 2024 Annual Meeting of Stockholders. The company announced the
• Protagonist Therapeutics Files 8-K on Financials — May 7, 2024 Risk: low
  Protagonist Therapeutics, Inc. filed an 8-K on May 7, 2024, reporting on its results of operations and financial condition, as well as financial statements and
• Protagonist Therapeutics Files 8-K for Financial Results — Feb 27, 2024 Risk: medium
  Protagonist Therapeutics, Inc. filed an 8-K on February 27, 2024, to report its results of operations and financial condition, along with related financial stat
• Protagonist Therapeutics Enters Material Definitive Agreement — Jan 31, 2024
  Protagonist Therapeutics, Inc. filed an 8-K on January 31, 2024, to report an "Entry into a Material Definitive Agreement." This filing indicates that the compa
• Protagonist Therapeutics Signals Potential Strategic Activity via 8-K — Jan 16, 2024
  Protagonist Therapeutics, Inc. filed an 8-K on January 16, 2024, reporting an event that occurred on January 9, 2024. This filing indicates the company is using
• Protagonist Therapeutics Files Routine 8-K for Disclosure — Jan 8, 2024
  Protagonist Therapeutics, Inc. filed an 8-K on January 8, 2024, indicating a routine filing for Regulation FD Disclosure and Financial Statements and Exhibits.

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX